IL-12 Modulator

Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

Pomalidomide-d₄ (CC-4047-d₄) is the deuterated-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

Pomalidomide-¹⁵N,¹³C₅ (CC-4047-¹⁵N,¹³C₅) is the ¹³C, ¹⁵N-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α.

Pomalidomide (Standard) (CC-4047 (Standard)) is the analytical standard of Pomalidomide (HY-10984). This product is intended for research and analytical applications. Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

Pomalidomide-d₃ (CC-4047-d₃) is the deuterated-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

Laricitrin is a natural product with multiple biological activities. Laricitrin inhibits the phosphorylation and DNA-binding activity of STAT3, and downregulates the expression of IL-10. Laricitrin acts as an immunomodulator to regulate the differentiation, maturation and function of dendritic cells (DCs). Laricitrin inhibits the migration and invasion of lung cancer cells, and ameliorates lung cancer progression. Laricitrin can be used in research related to hypertension and lung cancer.

Pomalidomide-¹³C₅ (CC-4047-¹³C₅) is the ¹³C-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

RO8323 is an orally active, selective CDK8/CDK19 inhibitor, with an IC₅₀ of 2 nM against CDK8 and 3 nM against CDK19. RO8323 promotes regulatory T cell differentiation, inhibits effector T cell generation, reverses the Teff/Treg ratio, upregulates IL-10 production in myeloid cells, and suppresses the production of TNF-α, IL-6 and IL-12. RO8323 enhances immune reconstitution and prolongs cardiac allograft survival in a dose-dependent manner. RO8323 can be used in the research of chronic graft-versus-host disease, cardiac allograft rejection, acute graft-versus-host disease and experimental autoimmune encephalomyelitis.

Pomalidomide-d₅ (CC-4047-d₅) is the deuterated-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.